

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

MEBENDAZOLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MEBENDAZOLE	EMVERM		43181	GPI-14	
				(15000010000505)	

GUIDELINES FOR USE

- 1. Does the patient have a diagnosis of *Enterobius vermicularis* (pinworm) infection and meet **ALL** of the following criteria?
 - The patient is 2 years of age or older
 - The patient had a trial of or contraindication to pyrantel pamoate (OTC)

If yes, approve for 1 month by GPID or GPI-14 with a quantity limit of #2. If no, continue to #2.

- 2. Does the patient have a diagnosis of *Trichuris trichiura* (whipworm) or *Ascaris lumbricoides* (common roundworm) infection and meet **ALL** of the following criteria?
 - The patient is 2 years of age or older
 - There is documentation (e.g., chart notes, lab results, diagnostic test results) confirming the diagnosis of *Trichuris trichiura* (whipworm) or *Ascaris lumbricoides* (common roundworm) infection
 - The patient had a trial of or contraindication to albendazole (Albenza)

If yes, approve for 1 month by GPID or GPI-14 with a quantity limit of #6. If no, continue to #3.

- 3. Does the patient have a diagnosis of *Ancylostoma duodenale* (common hookworm) or *Necator americanus* (American hookworm) infection and meet **ALL** of the following criteria?
 - The patient is 2 years of age or older
 - There is documentation (e.g., chart notes, lab results, diagnostic test results) confirming the diagnosis of Ancylostoma duodenale (common hookworm) or Necator americanus (American hookworm) infection
 - The patient had a trial of or contraindication to albendazole (Albenza) or pyrantel pamoate (OTC)

If yes, approve for 1 month by GPID or GPI-14 with a quantity limit of #6. If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 8/25/2023 Page 1 of 2



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

MEBENDAZOLE

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MEBENDAZOLE (Emverm)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of *Enterobius vermicularis* (pinworm), *Trichuris trichiura* (whipworm), *Ascaris lumbricoides* (common roundworm), *Ancylostoma duodenale* (common hookworm), or *Necator americanus* (American hookworm) infection
- B. You are 2 years of age or older
- C. If you have *Enterobius vermicularis* (pinworm) infection, approval also requires:
 - 1. You had a trial of or contraindication (harmful for) to over-the-counter (OTC) pyrantel pamoate
- D. If you have Trichuris trichiura (whipworm) or Ascaris lumbricoides (common roundworm) infection, approval also requires:
 - 1. There is documentation (such as chart notes, lab results, diagnostic test results) confirming your diagnosis of *Trichuris trichiura* (whipworm) or *Ascaris lumbricoides* (common roundworm) infection
 - 2. You had a trial of or contraindication (harmful for) to albendazole (Albenza)
- E. If you have Ancylostoma duodenale (common hookworm) or Necator americanus (American hookworm) infection, approval also requires:
 - 1. There is documentation (such as chart notes, lab results, diagnostic test results) confirming your diagnosis of *Ancylostoma duodenale* (common hookworm) or *Necator americanus* (American hookworm) infection
 - 2. You had a trial of or contraindication (harmful for) to albendazole (Albenza) OR over-the-counter (OTC) pyrantel pamoate

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Emverm.

REFERENCES

• Emverm [Prescribing Information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; August 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 03/16

Commercial Effective: 09/11/23 Client Approval: 08/23 P&T Approval: 07/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 8/25/2023 Page 2 of 2